Reply  by Tabata, Tomotsugu & Klein, Allan L.
REFERENCES
1. Tabata T, Thomas JD, Klein AL. Pulmonary venous flow by Doppler
echocardiography: revisited 12 years later. J Am Coll Cardiol 2003;41:
1243–50.
2. Arques S, Ambrosi P, Gelisse R, Luccioni R, Habib G. Hypoalbumin-
emia in elderly patients with acute diastolic heart failure. J Am Coll
Cardiol 2003;42:712–6.
3. Nishimura RA, Abel MD, Hatle LK, Tajik AJ. Relation of pulmonary vein
to mitral flow velocities by transesophageal Doppler echocardiography.
Effect of different loading conditions. Circulation 1990;81:1488–97.
4. Chirillo F, Brunazzi MC, Barbiero M, et al. Estimating mean pulmo-
nary wedge pressure in patients with chronic atrial fibrillation from
transthoracic Doppler indexes of mitral and pulmonary venous flow
velocity. J Am Coll Cardiol 1997;30:19–26.
5. Yamamuro A, Yoshida K, Ozumi T, et al. Noninvasive evaluation of
pulmonary capillary wedge pressure in patients with acute myocardial
infarction by deceleration time of pulmonary venous flow velocity in
diastole. J Am Coll Cardiol 1999;34:90–4.
6. Matsukida K, Kisanuki A, Toyonaga K, et al. Comparison of transtho-
racic Doppler echocardiography and natriuretic peptides in predicting
mean pulmonary capillary wedge pressure in patients with chronic atrial
fibrillation. J Am Soc Echocardiogr 2001;14:1080–7.
7. Gonzalez-Vilchez F, Ayuela J, Ares M, Mata NS, Gonzalez AG,
Duran RM. Comparison of Doppler echocardiography, color M-mode
Doppler, and Doppler tissue imaging for the estimation of pulmonary
capillary wedge pressure. J Am Soc Echocardiogr 2002;15:1245–50.
8. Kinnaird TD, Thompson CR, Munt BI. The deceleration time of
pulmonary venous diastolic flow is more accurate than the pulmonary
artery occlusion pressure in predicting left atrial pressure. J Am Coll
Cardiol 2001;37:2025–30.
REPLY
We thank Drs. Arques and Roux for their comments concerning
the increasing use of the deceleration time of the pulmonary
venous early diastolic flow (PV-DT) in published reports. We
agree that the PV-DT is a useful tool for estimating pulmonary
capillary wedge pressure (PCWP) as a measure of the left ventric-
ular (LV) filling pressure, especially in patients with normal sinus
rhythm. As mentioned in our study (1), it is important to recognize
the influence of several factors regarding use of pulmonary venous
flow velocities in clinical practice.
When evaluating PV-DT to estimate PCWP, the influences of
heart rate, mitral regurgitation (MR), atrial fibrillation (AF), and
LV systolic function have to be taken into account. Of those
factors, heart rate may have the largest influence on the PV-DT.
Chirillo et al. (2) specifically paid attention to the two components
of the deceleration slope of PV-DT. They speculated that the first
component was mainly dependent on the initial driving pressure of
the pulmonary venous flow, and the second component was
affected by the duration of LV relaxation, LV compliance, and
heart rate as reported by Little et al. (3). They found a strong
correlation between the initial deceleration slope of PV-DT and
PCWP during chronic AF with controlled ventricular rates. With
faster heart rates, it would be difficult to separate the first and
second components. Thus, PV-DT can estimate PCWP only
when the heart rates are relatively slow. Matsukida et al. (4) have
also reported that the PV-DT accurately predicted PCWP in
patients with AF, whereas they only included patients with a heart
rate of 60 to 80 beats/min. Both of the above investigators (2,4)
excluded patients with AF and a rapid ventricular rate. It is well
recognized that the loading conditions during AF are constantly
changing; therefore, even when an average of consecutive several
cardiac cycles of PV-DT is used, the value would vary depending
on the selected beats.
The final issue is the effect of MR. Pozzoli et al. (5) reported
that the PCWP can be reliably estimated by combining mitral
inflow and pulmonary venous flow velocities even when MR was
present. Although they have not evaluated PV-DT, the investiga-
tors have reported that the correlation between mitral deceleration
time and PCWP was stronger in patients without MR. Further-
more, they have limited their results to apply to patients without
atrial arrhythmias or tachycardia.
Thus, we conclude that the evaluation of the PV-DT for
estimating PCWP is most useful in patients without MR with
sinus rhythm and a relatively slower heart rate. As suggested by
Drs. Arques and Roux, we believe that the improvement in the
quality of pulmonary venous Doppler flow profile obtained by
transthoracic techniques will enhance the future use of PV flow in
clinical practice.
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Glycoprotein IIb/IIIa Inhibitors
and the Guidelines for Treatment of
Non–ST-Elevation Myocardial Infarction
In a recent study published in the Journal (1) Peterson et al. found
that with regard to use of glycoprotein (GP) IIb/IIIa inhibitors
there was a low adherence to American College of Cardiology/
American Heart Association guidelines (published in 2000) for
treatment of non–ST-elevation myocardial infarction (2), and they
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